PACS Group vs Rhythm Pharmaceuticals
PACS Group (PACS), health care, and Rhythm Pharmaceuticals (RYTM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Rhythm Pharmaceuticals is worth $8.1B on the stock market and PACS Group $7.7B: Rhythm Pharmaceuticals is valued at 5% more. PACS Group's operating margin in its latest fiscal year was 5.85% and Rhythm Pharmaceuticals's -101%. Over the past year PACS Group's share price has moved +240% and Rhythm Pharmaceuticals's +6.93%.
Key facts
- PACS Group market value
- $7.7B
- Rhythm Pharmaceuticals market value
- $8.1B
- PACS Group P/E
- 27.6
- PACS Group revenue
- $5.3BFY to 2025-12-31
- Rhythm Pharmaceuticals revenue
- $189.8MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | PACS Group | Rhythm Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.7Blower | $8.1Bhigher |
| Revenue | $5.3Bhigher | $189.8Mlower |
| Earnings | $191.5Mhigher | -$196.5Mlower |
| Employees | 47,455higher | 414lower |
| Total assets | $5.6Bhigher | $480.2Mlower |
| Valuation | ||
| P/E | 27.6 | — |
| P/S | 1.5lower | 42.6higher |
| P/B | 6.3lower | 91.9higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 5.85%higher | -101%lower |
| Balance sheet | ||
| Net assets | $946.8Mhigher | $139.1Mlower |
| Total liabilities | $4.6Bhigher | $210.2Mlower |
| Total debt | $353.2Mhigher | $108.2Mlower |
| Cash on hand | $197Mhigher | $54.3Mlower |
| Price change | ||
| Today | -0.92%lower | +8.49%higher |
| 1 year | +240%higher | +6.93%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
PACS Group only (1)
Rhythm Pharmaceuticals only (4)
Percentages are each holding's share of that investor's reported portfolio. Who owns PACS · Who owns RYTM
More on PACS Group
Further comparisons
PACS Group against its closest peers
Rhythm Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, PACS Group or Rhythm Pharmaceuticals?
By market value, Rhythm Pharmaceuticals is the larger: $8.1B against $7.7B for PACS Group. By revenue in its latest fiscal year, PACS Group is the larger: $5.3B against $189.8M for Rhythm Pharmaceuticals.
Which has the higher operating margin?
PACS Group: 5.85%, against -101% for Rhythm Pharmaceuticals. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
PACS Group: $353.2M, against $108.2M for Rhythm Pharmaceuticals. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both PACS Group and Rhythm Pharmaceuticals?
None of the tracked superinvestors holds both in their latest 13F filing. 1 holds PACS Group and 4 hold Rhythm Pharmaceuticals.
Cite this page
Funkfolio, “PACS Group vs Rhythm Pharmaceuticals”, data as of 18 November 2026. https://funkfolio.com/compare/pacs-vs-rytm
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.